Literature DB >> 2817216

Identification of Mycoplasma incognitus infection in patients with AIDS: an immunohistochemical, in situ hybridization and ultrastructural study.

S C Lo1, M S Dawson, D M Wong, P B Newton, M A Sonoda, W F Engler, R Y Wang, J W Shih, H J Alter, D J Wear.   

Abstract

Monoclonal antibodies (Mabs) were developed against antigens from a pure culture of Mycoplasma incognitus grown in modified SP-4 medium. All the Mabs obtained were shown to react only with M. incognitus, and not with other species of human mycoplasma. The Mabs identified M. incognitus immunohistologically in thymus, liver, spleen, lymph node, or brain from 22 patients with AIDS, as well as in 2 placentas delivered by patients with AIDS. Using an 35S-labeled DNA probe specific for M. incognitus and in situ hybridization technique, we also identified M. incognitus-specific genetic material in these tissues. Furthermore, ultrastructural studies of the specific areas of tissues which were highly positive for M. incognitus antigens revealed characteristic structures of mycoplasma organisms. These mycoplasma-like particles could be identified intracellularly and extracellularly. Histopathology of the tissues infected by M. incognitus varied from no pathological changes to fulminant necrosis with or without an associated inflammatory reaction. M. incognitus, a novel pathogenic mycoplasma, was cytopathic and cytocidal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817216     DOI: 10.4269/ajtmh.1989.41.601

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  32 in total

Review 1.  Mycoplasmas and arthritis.

Authors:  K Hakkarainen; H Turunen; A Miettinen; M Karppelin; K Kaitila; E Jansson
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

2.  Mycoplasma fermentans and TNF-beta interact to amplify immune-modulating cytokines in human lung fibroblasts.

Authors:  James P Fabisiak; Fei Gao; Robyn G Thomson; Robert M Strieter; Simon C Watkins; James H Dauber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06-02       Impact factor: 5.464

3.  Mycoplasmas and human arthritis.

Authors:  E Jansson; K Hakkarainen; A Miettinen; K Kaitila; M Karppelin
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

4.  Acid phosphatase purified from Mycoplasma fermentans has protein tyrosine phosphatase-like activity.

Authors:  K Shibata; M Noda; Y Sawa; T Watanabe
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

5.  Pathogenicity of Mycoplasma fermentans and Mycoplasma penetrans in experimentally infected chicken embryos.

Authors:  M M Hayes; B J Li; D J Wear; S C Lo
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  Genotypic and phenotypic analysis of Mycoplasma fermentans strains isolated from different host tissues.

Authors:  L Campo; P Larocque; T La Malfa; W D Blackburn; H L Watson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

7.  Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.

Authors:  S D Goodwin; H A Gallis; A T Chow; F A Wong; S C Flor; J A Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Intracellular location of Mycoplasma genitalium in cultured Vero cells as demonstrated by electron microscopy.

Authors:  J S Jensen; J Blom; K Lind
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

9.  Mycoplasma gallisepticum invades chicken erythrocytes during infection.

Authors:  Gunther Vogl; Astrid Plaickner; Susan Szathmary; László Stipkovits; Renate Rosengarten; Michael P Szostak
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

10.  Lipid-associated membrane proteins of Mycoplasma fermentans and M. penetrans activate human immunodeficiency virus long-terminal repeats through Toll-like receptors.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.